Biogen

Biogen Germany is one of the the largest biotech companies in Germany, and since its inception 26 years ago, it has been able to improve the lives of thousands of people suffering from serious illnesses such as multiple sclerosis or spinal muscular atrophy through research and innovative therapies. Biogen is still developing groundbreaking medications and solutions for patients all around the world. It undertakes research where others have reached their limits, giving sufferers with complex neurological and immunological disorders new hope.

Biogen is developing a pipeline of possible treatments in neurology, neuropsychiatry, specialized immunology, and rare illness, and the company is laser-focused on its mission of serving humanity through science and building a healthier, more sustainable, and equitable society. Biogen, as a pioneer, has been instrumental in driving medical development in neurology and biotechnology since its inception. Biogen is still developing groundbreaking medications and solutions that have the potential to enhance the lives of many individuals suffering from terrible illnesses.

Biogen has been at the forefront of numerous ground-breaking inventions, including a broad portfolio of medications to treat multiple sclerosis, the first licensed treatment for spinal muscular atrophy, and two co-developed therapeutics to target a distinguishing pathology of Alzheimer's disease. Biogen's mission is to enhance healthcare by pioneering research and worldwide development, manufacturing and commercial capabilities, and adhering to the commitment to and principles of sustainability.

Founded: 1997
Headquarters: München, Germany
Website: https://www.biogen.de/